- Home
- CHRS vs EFTY Comparison
CHRS vs EFTY Comparison
Compare CHRS & EFTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- EFTY
- Stock Information
- Founded
- CHRS 2010
- EFTY 2013
- Country
- CHRS United States
- EFTY Hong Kong
- Employees
- CHRS 177
- EFTY N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- EFTY
- Sector
- CHRS Health Care
- EFTY
- Exchange
- CHRS Nasdaq
- EFTY Nasdaq
- Market Cap
- CHRS 149.9M
- EFTY 113.6M
- IPO Year
- CHRS 2014
- EFTY 2025
- Fundamental
- Price
- CHRS $1.37
- EFTY $6.92
- Analyst Decision
- CHRS Strong Buy
- EFTY
- Analyst Count
- CHRS 4
- EFTY 0
- Target Price
- CHRS $4.51
- EFTY N/A
- AVG Volume (30 Days)
- CHRS 1.4M
- EFTY 436.3K
- Earning Date
- CHRS 11-05-2025
- EFTY 01-01-0001
- Dividend Yield
- CHRS N/A
- EFTY N/A
- EPS Growth
- CHRS N/A
- EFTY N/A
- EPS
- CHRS 1.55
- EFTY 0.05
- Revenue
- CHRS $272,209,000.00
- EFTY $2,525,909.00
- Revenue This Year
- CHRS N/A
- EFTY N/A
- Revenue Next Year
- CHRS $126.00
- EFTY N/A
- P/E Ratio
- CHRS $0.88
- EFTY $145.61
- Revenue Growth
- CHRS 52.33
- EFTY 3855.20
- 52 Week Low
- CHRS $0.66
- EFTY $3.88
- 52 Week High
- CHRS $2.43
- EFTY $8.49
- Technical
- Relative Strength Index (RSI)
- CHRS 73.83
- EFTY N/A
- Support Level
- CHRS $1.26
- EFTY N/A
- Resistance Level
- CHRS $1.39
- EFTY N/A
- Average True Range (ATR)
- CHRS 0.08
- EFTY 0.00
- MACD
- CHRS 0.02
- EFTY 0.00
- Stochastic Oscillator
- CHRS 94.10
- EFTY 0.00
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About EFTY Etoiles Capital Group Co. Ltd. Class A Ordinary Shares
Etoiles Capital Group Co Ltd specializes in providing integrated investor relations services within the financial industry.